Challenges in the use of DNA repair deficiency as a biomarker in breast cancer

Journal of Clinical Oncology

Volumn 33, Issue 17, 2015, Pages 1867-1869

  Schouten, Philip C ^a   Linn, Sabine C ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; GEMCITABINE; INIPARIB; ANTINEOPLASTIC AGENT; CISPLATIN; TUMOR MARKER;

BREAST METASTASIS; CHROMOSOME SIZE; DISORDERS OF DNA SYNTHESIS AND REPAIR; DNA REPAIR; EDITORIAL; GERMLINE MUTATION; HETEROZYGOSITY LOSS; HOMOLOGOUS RECOMBINATION; HUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TRIPLE NEGATIVE BREAST CANCER; ADJUVANT THERAPY; FEMALE; GENETICS; GENOMIC INSTABILITY; PROCEDURES; SEGMENTAL MASTECTOMY; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; FEMALE; GENOMIC INSTABILITY; HUMANS; MASTECTOMY, SEGMENTAL; NEOADJUVANT THERAPY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84937107044     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.5501     Document Type: Editorial

References (38)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
2. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
3. Bauer KR, Brown M, Cress RD, et al: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California Cancer Registry. Cancer 109:1721-1728, 2007
4. Linn SC, Van't Veer LJ: Clinical relevance of the triple-negative breast cancer concept: Genetic basis and clinical utility of the concept. Eur J Cancer 45:11-26, 2009
5. Hudis CA, Gianni L: Triple-negative breast cancer: An unmet medical need. Oncologist 16:1-11, 2011
6. Abramson VG, Lehmann BD, Ballinger TJ, et al: Subtyping of triple-negative breast cancer: Implications for therapy. Cancer 121:8-16, 2015
7. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4:814-819, 2004
8. Anders C, Carey LA: Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 22:1233-1239, 2008; discussion 1239-1240, 1243
9. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490:61-70, 2012
10. Moynahan ME, Chiu JW, Koller BH, et al: Brca1 controls homology-directed DNA repair. Mol Cell 4:511-518, 1999
11. Venkitaraman AR: Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol 4:461-487, 2009
12. Ciccia A, Elledge SJ: The DNA damage response: Making it safe to play with knives. Mol Cell 40:179-204, 2010
13. Deans AJ, West SC: DNA interstrand crosslink repair and cancer. Nat Rev Cancer 11:467-480, 2011
14. Helleday T: Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 31:955-960, 2010
15. Von Minckwitz G, Schneeweiss A, Loibl S, et al: Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol 15:747-756, 2014
16. Sikov WM, Berry DA, Perou CM, et al: Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 33:13-21, 2015
17. Sparano JA: Defining a role and predicting benefit from platinum-based therapy in breast cancer: An evolving story. J Clin Oncol 33:1-3, 2015
18. Telli ML, Jensen KC, Vinayak S, et al: Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol 33:1895-1901, 2015
19. Isakoff SJ, Mayer EL, He L, et al: TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 33:1902-1909, 2015
20. Abkevich V, Timms KM, Hennessy BT, et al: Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 107:1776-1782, 2012
21. Popova T, Manié E, Rieunier G, et al: Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 72:5454-5462, 2012
22. Watkins JA, Irshad S, Grigoriadis A, et al: Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res 16:211, 2014
23. Bayraktar S, Glück S: Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Res Treat 135:355-366, 2012
24. Imyanitov EN, Moiseyenko VM: Drug therapy for hereditary cancers. Hered Cancer Clin Pract 9:5, 2011
25. Francken AB, Schouten PC, Bleiker EM, et al: Breast cancer in women at high risk: The role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies. Breast 22:561-568, 2013
26. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009
27. Henry NL, Hayes DF: Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist 11:541-552, 2006
28. Sargent DJ, Conley BA, Allegra C, et al: Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23:2020-2027, 2005
29. Mandrekar SJ, Sargent DJ: Clinical trial designs for predictive biomarker validation: One size does not fit all. J Biopharm Stat 19:530-542, 2009
30. McShane LM, Altman DG, Sauerbrei W, et al: REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229-235, 2006
31. Altman DG, McShane LM, Sauerbrei W, et al: Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and elaboration. PLoS Med 9:e1001216, 2012
32. Schouten PC, Marmé F, Aulmann S, et al: Breast cancers with a BRCA1-like DNA copy number profile recur less often than expected after high-dose alkylating chemotherapy. Clin Cancer Res 21:763-770, 2015
33. th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2014 (abstr S3-01)
34. Birkbak NJ, Wang ZC, Kim JY, et al: Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2:366-375, 2012
35. Timms KM, Abkevich V, Hughes E, et al: Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res 16:475, 2014
36. Glas A, Peeters J, Yau C, et al: Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL. Eur J Cancer 50:173, 2014
37. Vollebergh MA, Lips EH, Nederlof PM, et al: An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 22:1561-1570, 2011
38. Schouten PC, Gluz O, Harbeck N, et al: BRCA1-like copy number profiles to predict benefit of high-dose alkylating chemotherapy in high-risk breast cancer (BC): Results from randomized WSG AM-01 trial. J Clin Oncol 32, 2014 (suppl 5s; abstr 11018)